Bedrocan and Becanex launch joint cannabis product push in Germany

By AI, Created 8:15 AM UTC, May 26, 2026, /AGP/ – Bedrocan and Berlin-based Becanex are launching a strategic product cooperation in Germany, their first shared market, with a public rollout set for industry events in London and Berlin in May 2026. The move pairs Bedrocan’s standardized cultivation with Becanex’s pharmaceutical extraction as Germany’s medical cannabis market grows and regulations continue to shift.

Why it matters: - The cooperation pairs two parts of the medicinal cannabis supply chain that are increasingly important in Germany: standardized cultivation and pharmaceutical extraction. - The partnership targets pharmacy compounding, where demand for standardized, high-quality cannabis ingredients is rising. - The launch adds a European supply-chain angle at a time when Germany still relies heavily on imports.

What happened: - Bedrocan and Becanex are launching a strategic product cooperation. - Germany is the first market where the two companies are appearing together. - The public kick-off is set for May 2026 at two industry events in the same week: Cannabis Europe in London and the Medical Cannabis Conference in Berlin. - The companies said the cooperation builds on a relationship that began more than a decade ago. - In 2014, Becanex co-founder Eral Osmanoglou’s team worked with Bedrocan under a scientific licence.

The details: - Bedrocan brings more than two decades of experience in standardized cultivation. - Bedrocan produces in EU-GMP-certified facilities in the Netherlands and Denmark. - Becanex provides pharmaceutical extraction from its Berlin production site. - Becanex’s Berlin site holds a manufacturing authorization under Section 13(1) of the German Medicines Act. - The Berlin site also holds a GMP certificate. - Becanex is registered as an active substance manufacturer under Section 64(3g) of the German Medicines Act. - Sebastian Kamphorst said Becanex’s team developed the first concentrates from Bedrocan flower together with Bedrocan under a scientific licence in 2014. - Jaap Erkelens said Bedrocan focuses on precise cultivation and Becanex on precise extraction. - The companies say they share a view that medicinal cannabis should meet the same standards of diligence, standardization and transparency as other pharmaceutical active ingredients. - Bedrocan and Becanex have production sites in the Netherlands, Denmark and Germany. - The companies say that footprint supports a European value chain with short transport distances and established regulatory standards. - More information is available through Bedrocan and Becanex.

Between the lines: - The timing reflects a German market that has expanded quickly since the Medicinal Cannabis Act took effect in April 2024. - BfArM data shows import volumes rose from around 72 tonnes in 2024 to approximately 201 tonnes in 2025. - The market is shifting toward standardized products for pharmacy compounding as demand grows. - The Bundestag is debating an amendment to the Medicinal Cannabis Act. - Possible changes to the benefits catalogue are also being discussed in the statutory health insurance financing debate. - The cooperation appears designed to position both companies around regulated, pharmaceutical-grade supply rather than consumer-oriented cannabis. - The long gap between the 2014 research work and this product cooperation suggests a move from scientific collaboration to commercialization.

What’s next: - Bedrocan and Becanex say the cooperation is a longer-term roadmap rather than a one-off launch. - Joint research and development is part of the plan. - The companies also plan joint healthcare-professional information activities. - Further steps will be announced later.

The bottom line: - Bedrocan and Becanex are betting that Germany’s fast-growing medical cannabis market will reward European, GMP-based supply chains built for pharmacy-grade use.